Adamas Pharmaceuticals Inc (ADMS) Stock News

NASDAQ:ADMS - Common Stock

8.22

+0.06 (+0.74%)

Last: 11/23/2021, 4:18:38 PM

8.3

+0.08 (+0.97%)

After Hours: 11/23/2021, 4:18:38 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ADMS Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Glancy Prongay & Murray LLP

News Image

Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS

4 years ago - By: Benzinga - Mentions: TX AMWD TRIL CMC ...

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021

4 years ago - By: The Business Journals

East Bay drug maker's potential sale brings lawsuits, job cuts

4 years ago - By: Zacks Investment Research

Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know

4 years ago - By: The Business Journals - Mentions: SUPN

For a few dollars more: Behind the half-billion-dollar deal for an East Bay Parkinson's Disease drug company

4 years ago - By: Halper Sadeh LLP - Mentions: UMPQ XLRN AZPN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

4 years ago - By: The Motley Fool - Mentions: SUPN

Why Supernus' Acquisition of Adamas Is a Smart Move

4 years ago - By: Kahn Swick & Foti, LLC

ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS

4 years ago - By: Benzinga - Mentions: ZH AMKR NKE DKNG ...

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021

4 years ago - By: WeissLaw LLP - Mentions: SUPN

SHAREHOLDER ALERT: WeissLaw LLP Investigates Adamas Pharmaceuticals, Inc.

4 years ago - By: The Business Journals

East Bay Parkinson's drug maker to be swallowed up in potential $450M deal

4 years ago - By: Invezz - Mentions: SUPN

Supernus Pharmaceuticals to acquire this Pharmaceuticals company for $400 million

4 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus

4 years ago - By: InvestorPlace - Mentions: SUPN

ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News

4 years ago - By: Halper Sadeh LLP

Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS

4 years ago - By: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grants

4 years ago - By: Adamas Pharmaceuticals, Inc.

Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards

4 years ago - By: Adamas Pharmaceuticals, Inc.

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress

4 years ago - By: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grants